WO2002007809A1 - Drug delivery and catheter systems, apparatus and processes - Google Patents
Drug delivery and catheter systems, apparatus and processes Download PDFInfo
- Publication number
- WO2002007809A1 WO2002007809A1 PCT/US2001/023187 US0123187W WO0207809A1 WO 2002007809 A1 WO2002007809 A1 WO 2002007809A1 US 0123187 W US0123187 W US 0123187W WO 0207809 A1 WO0207809 A1 WO 0207809A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- tube
- holes
- delivery
- catheter
- user
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims abstract description 61
- 230000008569 process Effects 0.000 title claims description 16
- 238000012377 drug delivery Methods 0.000 title description 17
- 239000000463 material Substances 0.000 claims abstract description 62
- 239000012530 fluid Substances 0.000 claims abstract description 47
- 239000000725 suspension Substances 0.000 claims abstract description 6
- 238000003780 insertion Methods 0.000 claims abstract description 4
- 230000037431 insertion Effects 0.000 claims abstract description 4
- 210000001519 tissue Anatomy 0.000 claims description 43
- 239000012528 membrane Substances 0.000 claims description 32
- 230000000694 effects Effects 0.000 claims description 12
- 238000009826 distribution Methods 0.000 claims description 11
- 238000013461 design Methods 0.000 claims description 8
- 206010030113 Oedema Diseases 0.000 claims description 7
- 210000004204 blood vessel Anatomy 0.000 claims description 7
- 239000000523 sample Substances 0.000 claims description 7
- 230000006378 damage Effects 0.000 claims description 5
- 238000009792 diffusion process Methods 0.000 claims description 3
- 238000003384 imaging method Methods 0.000 claims description 3
- 238000005086 pumping Methods 0.000 claims description 3
- 210000000988 bone and bone Anatomy 0.000 claims description 2
- 238000005553 drilling Methods 0.000 claims description 2
- 238000012800 visualization Methods 0.000 claims description 2
- 102000002067 Protein Subunits Human genes 0.000 claims 4
- 108010001267 Protein Subunits Proteins 0.000 claims 4
- 230000037361 pathway Effects 0.000 claims 1
- 210000004872 soft tissue Anatomy 0.000 claims 1
- 239000003814 drug Substances 0.000 abstract description 36
- 229940079593 drug Drugs 0.000 abstract description 24
- 238000002347 injection Methods 0.000 abstract description 19
- 239000007924 injection Substances 0.000 abstract description 19
- 238000011282 treatment Methods 0.000 abstract description 14
- 238000010276 construction Methods 0.000 abstract description 6
- 239000003795 chemical substances by application Substances 0.000 description 15
- 238000001802 infusion Methods 0.000 description 11
- 230000009286 beneficial effect Effects 0.000 description 6
- 230000010412 perfusion Effects 0.000 description 6
- 230000008685 targeting Effects 0.000 description 6
- 230000001965 increasing effect Effects 0.000 description 5
- 230000035699 permeability Effects 0.000 description 5
- 229940124597 therapeutic agent Drugs 0.000 description 5
- 208000007536 Thrombosis Diseases 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 239000002870 angiogenesis inducing agent Substances 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 238000004891 communication Methods 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 230000007246 mechanism Effects 0.000 description 4
- 238000002663 nebulization Methods 0.000 description 4
- 239000011148 porous material Substances 0.000 description 4
- 210000002345 respiratory system Anatomy 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 239000008280 blood Substances 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 230000021164 cell adhesion Effects 0.000 description 3
- 238000002595 magnetic resonance imaging Methods 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 239000013610 patient sample Substances 0.000 description 3
- 238000011179 visual inspection Methods 0.000 description 3
- 206010028980 Neoplasm Diseases 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 239000011149 active material Substances 0.000 description 2
- 102000019997 adhesion receptor Human genes 0.000 description 2
- 108010013985 adhesion receptor Proteins 0.000 description 2
- 239000000853 adhesive Substances 0.000 description 2
- 230000001070 adhesive effect Effects 0.000 description 2
- 230000033115 angiogenesis Effects 0.000 description 2
- 239000005557 antagonist Substances 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 238000009513 drug distribution Methods 0.000 description 2
- 230000004907 flux Effects 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 230000033001 locomotion Effects 0.000 description 2
- 238000012544 monitoring process Methods 0.000 description 2
- 230000035479 physiological effects, processes and functions Effects 0.000 description 2
- MFOUDYKPLGXPGO-UHFFFAOYSA-N propachlor Chemical compound ClCC(=O)N(C(C)C)C1=CC=CC=C1 MFOUDYKPLGXPGO-UHFFFAOYSA-N 0.000 description 2
- 239000002464 receptor antagonist Substances 0.000 description 2
- 229940044551 receptor antagonist Drugs 0.000 description 2
- 238000005070 sampling Methods 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 230000000007 visual effect Effects 0.000 description 2
- 229930000680 A04AD01 - Scopolamine Natural products 0.000 description 1
- 201000004384 Alopecia Diseases 0.000 description 1
- 206010012689 Diabetic retinopathy Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- STECJAGHUSJQJN-GAUPFVANSA-N Hyoscine Natural products C1([C@H](CO)C(=O)OC2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-GAUPFVANSA-N 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- STECJAGHUSJQJN-UHFFFAOYSA-N N-Methyl-scopolamin Natural products C1C(C2C3O2)N(C)C3CC1OC(=O)C(CO)C1=CC=CC=C1 STECJAGHUSJQJN-UHFFFAOYSA-N 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 102000003990 Urokinase-type plasminogen activator Human genes 0.000 description 1
- 108090000435 Urokinase-type plasminogen activator Proteins 0.000 description 1
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 1
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 210000003484 anatomy Anatomy 0.000 description 1
- 230000002491 angiogenic effect Effects 0.000 description 1
- 238000002399 angioplasty Methods 0.000 description 1
- 230000001062 anti-nausea Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000002457 bidirectional effect Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000012292 cell migration Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 229940044683 chemotherapy drug Drugs 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 239000000599 controlled substance Substances 0.000 description 1
- 238000007887 coronary angioplasty Methods 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 239000004078 cryogenic material Substances 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000002716 delivery method Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 230000005489 elastic deformation Effects 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 210000003722 extracellular fluid Anatomy 0.000 description 1
- 239000003527 fibrinolytic agent Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 208000024963 hair loss Diseases 0.000 description 1
- 230000003676 hair loss Effects 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 230000002706 hydrostatic effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 102000006495 integrins Human genes 0.000 description 1
- 108010044426 integrins Proteins 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 238000007917 intracranial administration Methods 0.000 description 1
- 238000005304 joining Methods 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 230000002934 lysing effect Effects 0.000 description 1
- 208000002780 macular degeneration Diseases 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 239000002357 osmotic agent Substances 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 230000002572 peristaltic effect Effects 0.000 description 1
- 230000002688 persistence Effects 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 230000010349 pulsation Effects 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 208000037803 restenosis Diseases 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- STECJAGHUSJQJN-FWXGHANASA-N scopolamine Chemical compound C1([C@@H](CO)C(=O)O[C@H]2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-FWXGHANASA-N 0.000 description 1
- 229960002646 scopolamine Drugs 0.000 description 1
- 238000010187 selection method Methods 0.000 description 1
- 238000004088 simulation Methods 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 238000011287 therapeutic dose Methods 0.000 description 1
- 229940126585 therapeutic drug Drugs 0.000 description 1
- 230000009424 thromboembolic effect Effects 0.000 description 1
- 229960000103 thrombolytic agent Drugs 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- 229960005356 urokinase Drugs 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 238000003466 welding Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M25/00—Catheters; Hollow probes
- A61M25/0067—Catheters; Hollow probes characterised by the distal end, e.g. tips
- A61M25/0068—Static characteristics of the catheter tip, e.g. shape, atraumatic tip, curved tip or tip structure
- A61M25/007—Side holes, e.g. their profiles or arrangements; Provisions to keep side holes unblocked
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S977/00—Nanotechnology
- Y10S977/902—Specified use of nanostructure
- Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
- Y10S977/906—Drug delivery
Definitions
- the present invention relates to a class of devices supplemented by computer supported designed-in variability, so that the user can make choices more accurately aimed at successfully accomplishing particular results.
- the present invention relates to the field of delivery of materials into a patient, particularly at local sites within a patient using externally delivered devices to carry the materials to the desired site.
- the invention also relates to systems and processes for material delivery (especially pharmacologically active, view enhancing active or treatment active materials) to patients under Magnetic Resonance Imaging procedures.
- these adverse side effects arise only where the drug reaches a specific tissue. Therefore, restricting the drug to a target that does not include tissue that can be damaged avoids side effects completely. Even where that degree of precision in delivery is not possible, the side effects may be far more acceptable if limited to a small region around the target, with reduced impact on the body at large, while delivering the desired result on the target tissue at full strength. Even where the side effects are not directly life-threatening, it can be important to avoid them. For example, it is desirable to keep cancer chemotherapy drugs from the sites where they cause nausea and hair loss. That practice would be good both for patient morale and for patient persistence in taking the drug.
- Some drug therapies use very strong or even toxic materials in the treatment, and even cryogenic treatments can cause collateral damage as the cryogenic material contacts non-targeted tissue.
- Hormonal treatments where picogram delivery volumes are used because of the strength or activity of the material delivered and/or the limited area of treatment desired, can cause significant collateral damage when inappropriately delivered. This is particularly true in intraparenchymal procedures and other intracranial procedures where collateral damage, even on a small physical scale, can be very serious.
- the majority of directed drug delivery systems tend to be essentially universal systems (intravenous or oral), ⁇ discriminate local application (transdermal), or mdiscrirninate quasi-local (infusion from a catheter). Even the most advanced designs for MRI observable drug delivery as disclosed in U.S. Patent Nos.
- 6,026,316; and 5,964,705 can only properly position the catheter, but do not provide specific structures that can adjust the rate and position of drug delivery from the catheter other than by standard fluid pressure control.
- Many different functions and controls are desirable in drug delivery systems, particularly with respect to the rate and direction of drug delivery. It would be a poor operational protocol to require essentially random direction positioning on a catheter of delivery outlets for a drug, cell culture, nanoscopic devices or other material, or require increased volumetric delivery, solely because the catheter could not be positioned with the outlets in an optimized position for desired delivery.
- U.S. Patent No. 6,029,083 describes a "fail-safe" iontophoretic drug delivery apparatus and a corresponding method is provided.
- the apparatus includes a current generating circuit for sending a current through a patch, error detection circuitry, and a control circuit.
- the control circuit controls the current generating circuit. When errors are detected in the apparatus, the control circuit stops the current and disables itself.
- U.S. Patent No. 6,017,318 describes a feedback controlled drug delivery system that includes the automated sampling and analysis of a patient sample and dosing the patient based on the analysis. Automated sampling may be performed by direct analysis of the patient sample, such as for the measurement of a blood sample coagulation state or a glucose level.
- the drug delivery system includes a sample set that has a bidirectional patient tube that allows for delivery of the patient sample to an analyzer, and at another time, the infusion of a therapeutic drug.
- a controller receives a measurement from the analyzer, and based on that measurement, adjusts the delivery of the therapeutic fluid.
- the sample set has a quick-clear Leur fitting that allows for more effectively clearing a first fluid from a Leur fitting when starting a second fluid.
- the system also has a reagent cassette holder that protects, using a foam gasket, a reagent on a sample slide. Further, the system provides an interlock apparatus that assures a sample tube is occluded by either or both a slide clamp and by a platen arm compressing the sample tube to a peristaltic pump.
- U.S. Patent No. 6,007,518 describes a fluid delivery apparatus comprising:
- a fluid delivery assembly having an outlet for delivering fluid from the apparatus, said fluid delivery assembly including: (i) a base; (ii) means defining a conformable ullage overlaying said base for forming in conjunction therewith a reservoir having an outlet in communication with said outlet of said fluid delivery assembly;
- a cover assembly connected to said base, one of said cover assembly and said base having a receiving chamber interconnected with said reservoir; and (iv) a stored energy means for exerting forces on said means defining a conformable ullage, said stored energy means comprising at least one distensible membrane superimposed over said means defining a conformable ullage, said membrane being distensible by forces imparted thereon by said means defining a conformable ullage in response to fluids introduced into said reservoir, said forces establishing internal stresses within said distensible membrane, said stresses tending to return said distensible membrane toward a less distended configuration, said distensible membrane being generally conformable to the shape of said means defining a conformable ullage as said membrane is being distended thereby and also being generally conformable to the shape of said means defining a conformable ullage as said distensible membrane tends to return to said less distended configuration; and
- U.S. Patent No. 5,997,527 describes a delivery device having a first chamber containing an osmotic agent, a membrane forming a wall of the first chamber through which fluid is imbibed by osmosis, a second chamber containing a beneficial agent to be delivered, and a moveable piston separating the two chambers.
- an orifice In fluid communication with the second chamber is an orifice which comprises a slit valve.
- the beneficial agent pushes through the slit, opening up a channel for delivery of the beneficial agent and creating flow.
- the slit valve opens only to the minimum dimension required to allow the flow generated by the osmotic pumping rate.
- the slit valve also allows a flow path to open around any obstruction in the slit valve to prevent clogging.
- U.S. Patent No. 5,988,211 describes a method and apparatus for control of flow through an I.V. system, not a catheterized delivery system.
- That I.V. system comprises an I.V. Flow Controller incorporating an adjustable, differential pressure regulator that provides a constant but adjustable differential pressure across a fixed orifice.
- One end of the adjustment range provides shut-off and the other end full-flow.
- the adjustment range covers flow rates from zero to 250 ml/hr. At a given setting, the flow rate is independent of the total hydrostatic head height between the supply reservoir and a patient, provided the head height is greater than the pressure drop across the orifice at the maximum regulated flow rate, plus venous pressure, plus the pressure drop in the indwelling catheter.
- U.S. Patent No. 5,983,130 describes an electrically controlled delivery system comprising an electrotransport agent delivery device for delivering a therapeutic agent through a body surface, and a method for increasing agent delivery efficiency, is provided.
- the device includes a current controller which delivers a pulsating electrotransport current and peak current density I max , I max being greater than a critical current density level I c above which the body exhibits a non-transitory higher agent delivery efficiency.
- Methods for increasing electrotransport delivery efficiency (E) of an agent through a body surface by creation of a higher agent delivery efficiency state are also provided.
- U.S. Patent No. 5,964,223 describes a method and apparatus for delivering a medicine to a patient via the patient's respiratory system with control and efficiency.
- a nebulization catheter is positioned in the patient's respiratory system so that a distal end of the nebulization catheter is in the respiratory system and a proximal end is outside the body.
- the nebulization catheter may be used in conjunction with an endotracheal tube and preferably is removable from the endotracheal tube.
- the nebulization catheter conveys medicine in liquid form to the distal end at which location the medicine is nebulized by a pressurized gas or other nebulizing mechanism.
- the nebulized medicine is conveyed to the patient's lungs by the patient's respiration which may be assisted by a ventilator.
- the nebulizing catheter By producing the aerosol of the liquid medicine at a location inside the patient's respiratory system, the nebulizing catheter provides for increased efficiency and control of the dosage of medicine being delivered.
- alternative tip constructions, flow pulsation patterns, centering devices, sensing devices, and aspiration features afford greater efficiency and control of aerosolized medicine dosage delivery.
- U.S. Patent No. 5,961,483 describes novel methods and devices for iontophoreticalfy administering therapeutic doses of cell adhesion receptor antagonists in a controlled manner through the skin.
- Such antagonist compounds include but are not limited to antagonists of the Ilb/IIIa and ⁇ v ⁇ 3 integrins and related cell surface adhesive protein receptors.
- the present invention includes iontophoretic delivery devices comprising cell adhesion receptor antagonists.
- Such methods and devices are useful, alone or in combination with other therapeutic agents, for the treatment of thromboembolic disorders, angiogenic disorders, inflammation, bone degradation, cancer metastasis, diabetic retinopathy, restenosis, macular degeneration, and other conditions mediated by cell adhesion and/or cell migration and/or angiogenesis.
- U.S. Patent No. 5,941,868 describes Angiogenesis in cardiac and other tissues being promoted by the transmural delivery of angiogenic factors such as VEGF, FGF, EGF, and PDGF, through blood vessels and other body lumens into the surrounding tissue.
- angiogenic factors such as VEGF, FGF, EGF, and PDGF
- the angiogenic factor is delivered using a catheter having infusion parts at its distal end.
- the distal end of the catheter is radially expanded to engage the infusion parts directly against the blood vessel wall.
- a variety of catheter systems useful for the direct transmural infusion of angiogenic factors into the blood vessel wall are also well-described in the patent literature.
- balloon catheters having expandable distal ends capable of engaging the inner wall of a blood vessel and infusing an angiogenic factor directly therein are well-described in the patent literature. See, for example, U.S. Pat. Nos. 5,318,531; 5,304,121; 5,295,962; 5,286,254; 5,254,089; 5,213,576; 5,197,946; 5,087,244; 5,049,132; 5,021,044; 4,994,033; and 4,824,436.
- Catheters having spaced-apart or helical balloons for expansion within the lumen of a blood vessel and delivery of a therapeutic agent to the resulting isolated treatment site are described in U.S. Pat. Nos.
- U.S. Patent No. 5,906,502 describes an apparatus for accurately infusing fluids into a patient at specific rates over an extended period of time and the method for making same.
- the apparatus includes one or more dispensers of a low profile, laminate or layered construction each having a stored energy source in the form of a distensible membrane or an elastomeric cellular mass, which in cooperation with the base, defined a fluid chamber having a fluid inlet and a fluid outlet.
- the apparatus further includes, in lieu of a rigid ullage, a high novel, conformable ullage made of yieldable materials. The conformable ullage uniquely conforms to the shape of elastomeric membrane as the membrane returns to its less distended configuration.
- the ullage can be located either between the base and the fluid to be delivered, or alternatively, can be located between the elastomeric membrane and the fluid to be delivered. Further, a plurality of sub-reservoirs can be associated with a single ullage thereby making it possible to incorporate a wide variety of delivery profiles within a single device.
- U.S. Patent Nos. 5,571,089; 5,542,926; and 5,522,800 describe a Low Profile Perfusion Catheter, for use in coronary angioplasty applications.
- the catheter is provided with an inflatable dilatation balloon, and a perfusion lumen extending therethrough.
- the diameter of the perfusion lumen is enlargeable from a first, reduced diameter to a second, enlarged diameter.
- an axially movable tubular support is movable within the lumen from a proximal, insertion position to a distal perfusion position.
- the support is radially expandable.
- a porous drug delivery balloon is provided.
- U.S. Patent No. 5,385,547 describes a drug delivery device for coupling a first container including a beneficial agent to a second member.
- the device includes a substantially hollow member having a cannula mounted within a wall that divides the substantially hollow member into a first and second section.
- the first section includes means for receiving at least a portion of a first container.
- the substantially hollow member includes a wall that defines an exterior of the first section that is substantially flexible. A number of different cannula and flow path structures within the hollow member are possible.
- U.S. Patent No. 5,498,236 describes a catheter suitable for introduction into a tubular tissue for dissolving blockages in such tissue.
- the catheter is particularly useful for removing thrombi within blood vessels.
- a combination of vibrating motion and injection of a lysing agent is utilized to break up blockages in vessels.
- the vessels may be veins, arteries, ducts, intestines, or any lumen within the body that may become blocked from the material that flows through it.
- dissolution of vascular thrombi is facilitated by advancing a catheter through the occluded vessel, the catheter causing a vibrating stirring action in and around the thrombus usually in combination with the dispensing of a thrombolytic agent such as urokinase into the thrombus.
- the catheter has an inflatable or expandable member near the distal tip which, when inflated or expanded, prevents the passage of dislodged thrombus around the catheter.
- the dislodged portions of thrombus are directed through a perfusion channel in the catheter, where they are removed by filtration means housed within the perfusion channel before the blood exits the tip of the catheter.
- U.S. Patent Nos. 5,800,392 and 5,569,198 describe an apparatus for delivering an agent to a treatment area.
- the apparatus includes a catheter that has a distal portion and a proximal portion.
- the catheter defines a lumen.
- a pressure regulator is in fluid communication with the lumen.
- a selectively inflatable member is also in fluid communication with the lumen, and is formed from a membrane.
- the membrane has first and second portions.
- the first portion defines pores sized from about 0.05 ⁇ to about l ⁇ and has a pore density from about 10 6 pores/cm 2 to about 10 9 pores/cm 2 .
- the flux rate is from about 0.001 ml/(min-cm 2 -atm) to about 0.4 ml/(min-cm 2 -atm).
- the second portion is substantially impermeable.
- U.S. Patent No. 5,783,793 describes a laser drilling process capable of producing a plurality of holes in a pharmaceutical dosage form at high speed.
- the process utilizes a high power CO 2 laser steered by an acousto-optic deflector together with various mirrors and optical components to achieve the correct beam path geometry, in order to produce an unlimited number of holes through the surface or coating of a dosage form, at rates up to 100,000 units or more per hour.
- restricted area targeting is highly desirable from a medical standpoint, this type of procedure adds to the traditional complexity of computing dosage and delivery rates.
- concentration becomes a distinct time- varying number at each part of the body. Since the effects of a drug vary in complex ways on concentration (scopolamine, for example, is an anti-nausea drug in a narrow range of levels, neither too high nor too low), its administration must ensure that the concentration at the target tissue is correct for the desired effect. At the same time, the concentration at other points must minimize undesired effects (often, but not always, by minimizing concentration at such points). Planning treatments and procedures thus requires prediction and flexibility of drug (or material) delivery.
- the present invention defines a class of customizable injection devices or delivery instruments whose basic form is a stiff tube with holes of user-selectable size at several user-selectable places, whose use includes a method of selection and construction of a particular device from such a class of devices for a particular treatment procedure using computer-assisted means.
- the user may make selections among the available choices (such as selection of hole size, selection of hole location, etc.), and a method can be practiced for making such user-selection serve the goals of delivery of materials such as drugs, cells, or of devices sufficiently small and numerous to be delivered in fluid suspension.
- the tube is relatively stiff in the sense that it deflects by an amount between 0° and 15° under the stresses of insertion and placement at the end of a catheter, and varies less than 5 or less than 10% per cent in cross-sectional area when so deflected to the maximum of about 15 degrees.
- the selection method may be practiced as follows.
- the user selects target tissues where the presence of the material is desired, and selects maximum and minimum target concentrations, and identifies tissues vulnerable to the material to be introduced, with maximum permitted concentrations identified in the region of the vulnerable tissues.
- This target information may be retained in the user's consciousness, or input to the machine by use of an interface, such as a visual interface (e.g., with pre-procedure image information or real-time image information).
- the user may then specify a hole pattern (e.g., a number of holes, a distribution of holes, the size of holes, the position of holes, etc.), and see the predicted result with a selected time course of imposed pressure (or imposed flow rate) of the material at a specified concentration in injected fluid.
- the user may request the system to explore different patterns (as defined above) and injection plans to produce a result satisfying the input criteria, or coming as close to such satisfaction as is acceptable or possible.
- Drawing 2 A tube tip with holes in various positions and dimensions, arranged by revolving collars over holes created in manufacture.
- Drawing 3 A tube tip with holes in various positions and dimensions, created by assembling cylindrical units with holes and membranes of different sizes.
- Drawing 4. A ramrod device for placing permeable barriers in a tube at preplanned positions.
- Drawing 6 A field of coefficients (here represented by a single number at each point, with a 2D grid standing for three dimensions) governing the transport of injected material.
- the physical component or device of the present invention is a tube (Drawing 1), rigid or sufficiently stiff to retain its internal cross-section (with a reduction not to exceed 10% and preferably equal to or less than 7% or 5%) when bent through a deflection of up to 15°, and deflecting by at most this amount under the stresses usual for an inserted catheter.
- the limitation on the change in cross-section is of significance because flexing of the device will often occur during procedures. If the cross-section alters, that would introduce a variation in device performance that would complicate the implementation of controls, as the flow and delivery rate properties of the device would change without intent.
- This tube is pre-engineered with holes 101 of adjustable sizes and positions, or capable of being drilled with holes of chosen sizes and positions.
- the tube may be mounted on a rigid or flexible channel 102 through which fluid containing dissolved or suspended material capable of moving through or onto bodily tissue may be transmitted to the interior of said tube. That material then passes through said holes to contact the tissue.
- one or more control mechanisms that can regulate the passage of material through the holes. Regulation includes all rates between complete blockage of material through the hole to allowing free passage of material through the hole.
- Such regulation and control mechanisms may be mechanical, electromechanical, or quasi-mechanical in nature.
- a purely mechanical control mechanism would be a slidable or rotatable cap that would obscure some holes, all holes, or portions of holes. For example, with a top of the element having twenty holes for release of material, there could be a cap with fifty holes distributed thereon.
- Rotation of the cap through ninety, one hundred twenty, one hundred sixty, one hundred eighty, or up to three hundred and sixty degrees would expose various portions or numbers of the twenty holes. For example, at a position defined as zero degree rotation, zero holes might be exposed (that is all twenty holes would be covered, preventing material delivery). At a five degree rotation, 1-3 holes at a specific position relative to the device would be exposed to allow delivery of material from those exposed holes. At a ten degree rotation, 3-5 holes at specific positions relative to the exterior of the device would be exposed. At a fifteen degree rotation, 5-8 holes at specific positions would be exposed to release material. At a twenty degree rotation, 9-12 holes would be exposed. At a thirty degree rotation, 12-15 holes would be exposed at specific positions on the outside of the device.
- 6,026,316 shows that the alignment of the device (e.g., a catheter) is delivering material too broadly (radially at all points along the tube surface) or in a quadrant facing away from the target tissue), the device may be remotely controlled by this mechanical control to redirect the output of material more closely towards the target tissue.
- Mechanical control could be effected by manipulation or mechanical control of a guidewire attached to the cap.
- Electromechanical control could employ electronically remote controlled servos or robotics that move caps, covers or the like around holes in the surface of the device. Micromotors could shift one or more hole-covering or hole-blocking elements to increase or decrease the rate of flow of material and the direction of flow of material from the device.
- a quasimechanical system would include resistively heated sections where flow would increase because of thermal expansion around or by holes; remotely initiated elastic deformation of caps to adjust the size of holes, and the like.
- Membranes may also be used that are electrically or thermally or elastically responsive to adjust flow rates through them.
- membranes 103 or blocks 104 of permeable material separate the holes, modifying the transmission characteristics of the fluid between them.
- the fabrication of the instrument may use any of a number of methods familiar to those skilled in the art. A wide selection of options may be pre-manufactured, saving on-site time at the expense of increased stock and storage costs.
- the preferred embodiment of the present invention is local customization, whereby the holes may be made or adjusted by the use of local equipment acting on a small set of standard parts, by various methods.
- the adjustability of the holes may be achieved in several ways.
- a plain tube is inserted in a jig and holes drilled into it with conical drill bits, so that the depth controls the hole diameter.
- this function can be performed by a small automated system, but equally a plan of the holes could be printed out on adhesive paper. The user would attach this printed hole distribution map to the tube, and drill the holes by hand, extending the current practice of radiologists in adjusting the active end of a catheter.
- the distribution of holes could be imaged on a photolithographic resist layer and the image developed and etched to produce the appropriate hole distribution.
- the tube may be manufactured with a closely spaced sequence of cylindrical collars (Drawing 2, in an exploded view). Under each collar 201 the tube is ringed with holes 202, alternating with regions 203 of un-pierced tube. Each collar has a single hole 204, which may be aligned partially or completely with any one of the holes, enabling the user to create a hole of varying cross-section in any one of a set of positions around the tube. To avoid unplanned leakage this requires precise engineering of a throwaway item, and is thus well suited to profitable medical engineering.
- the tube may also be assembled (Drawing 3) by sticking together short cylindrical segments 301 from a stock 310 of such pieces, with holes 311 and without holes 312, of varying lengths.
- some of the pieces 312 may contain permeable membranes 316 or blocks 317 whose permeability is marked on the outside, so that these may be added by the same assembly process.
- An optional cap 320 would allow the user to block the hole 321 at the end. If joining of the segments is performed by a heat- welding system in which one part must pass down the lumen of the combined tube, which would be blocked by the inclusion of permeable membranes, such membranes may be added later, as described in the discussion of Drawing 4.
- Holes may be photohthographically etched, laser etched, chemically milled, electrical discharge milled (EDM), or mechanically milled by other available procedures.
- Drawing 4 shows how permeable or discontinuously permeable slidable elements (permeable cylindrical blocks 201 or membranes 202) capable of lodging in the interior may be pushed down the tube to the required depth, using a calibrated ramrod 410 whose tip 411 pushes an element inside the tube.
- a calibrated ramrod 410 whose tip 411 pushes an element inside the tube.
- A Area of cross section of the catheter
- V Velocity of fluid infusion
- K -(P,-p l+i ) V ⁇ + ⁇ K J J(p a - Pj )
- Solving equation (6) gives the pressure at all the ports, and at the inlet and outlet ends. Since only pressure differences influence the flow, we have to fix (specify) one of the pressures; it is convenient to fix the ambient pressure (possibly to zero, in which case all other pressures are measured with respect to the ambient pressure). These pressure values obtained from (6) can be plugged back in the Darcy equations to give fluid outflow velocities at the ports, and thereby the fluid volume flow.
- the user-selection element of the present invention may proceed as follows:
- Image guidance permits a user injecting a material such as a drug solution or a suspension of cells or nanodevices, or any material that can flow and diffuse in the brain, to place a delivery instrument such as a catheter into (for example) a human brain, and see where it is located relative to scan-visible structures.
- a delivery instrument such as a catheter into (for example) a human brain, and see where it is located relative to scan-visible structures.
- the user makes a plan for injection, dete ⁇ riining the quantity of the material to be loaded into the delivery system, the pressure or flow rate (perhaps variable) at which the substance is to be injected, and the time over which the flow is to be maintained.
- the objective of such a plan is to deliver the substance in desired quantities in 'target' tissues, often while minimizing the amount delivered to non-target tissues (where it would be wasted) and to vulnerable tissues where the substance would do harm.
- this plan is entered into a computer which will control the injection process, but direct hand control is also possible.
- This plan is then followed, with a change only if visually inspected images (e.g., U.S. Patent No. 6,026,316) of the diffusing material makes clear that concentration, pressure or edema is not following the course expected by the user. Since the evolving concentration, pressure and edema are 3D scalar fields in the midst of complex 3D structures, visual inspection requires a strong grasp of the 3D relationships revealed by scan data.
- the present invention replaces or augments such visual inspection by enabling the computer to enter this part of the control loop, with optimal planning of the tube outlets as well as of the injection schedule.
- the user specifies a position for placement of the device (as is now done), and also specifies magnitude, distribution and location of holes and membranes.
- the user specifies an injection schedule (quantity, duration, pressure/flow-rate) to the computer.
- an injection schedule quantitative, duration, pressure/flow-rate
- the computer solves the transport problem on the assumption that this plan is followed, using the field of parameters established as in the above identified copending U.S. Patent Application "A Method and Apparatus for Targeting Material Delivery to Tissue", or otherwise, together with available subsidiary data such as background interstitial fluid pressure and blood pressure to specify boundary conditions.
- the system displays the predicted values of concentration, pressure and edema, and the user has the opportunity to examine them at non-crisis speed and determine whether they are satisfactory. If not, the user repeatedly changes the plan, until an acceptable result is predicted. At this point, the schedule is implemented under computer control.
- the user modifies the hole and membrane distribution by the use of a graphical user interface and specifies target tissues by marking them (for example, by using a 2D or 3D mouse to click on points, specifying ball-shaped regions of adjustable radius; or, outlining a target region; or, moving a 2D or 3D mouse through an image of the region of interest and seeing a resulting spray-can-like superposed image showing the intensity of target values so input for corresponding points, etc.
- Minimum and maximum target concentrations may be input separately.
- the user may mark vulnerable tissues, and quantify their vulnerability to excess concentration, pressure or edema. The user inputs a plan as above, and the computer predicts the resulting concentrations.
- the computer display includes markers for agreement with the user's goals, so that visual inspection is guided to possible regions of concern.
- the computer can monitor deviation from the expected time course of concentration, and detecting problems earlier (and thus more usefully) than visual monitoring. Where deviation beyond a threshold level is detected, the computer derives revised estimates for the transport parameters in the tissue and deduces revised predictions for the results of the plan. If these involve values pre-specified by the user as unacceptable, the computer may pause the injection for new user input.
- the computer may search the space of possible plans for the plan(s) with the result most quantitatively desirable according to the user- specified result.
- it may begin by heuristically choosing an initial plan, perhaps a standard one, and investigate the predicted result of successive changes in it, changing the current reference plan where it sees improved results.
- the physics will not allow exact achievement of a particular user-specified target concentration, pressure or edema, so this is not well posed as an inverse problem.
- plan(s) may be presented to the user, to be accepted or rejected by key-strokes, mouse click, voice, or other input means devoid of quantitative detail; or, the user may quantitatively modify the plan(s), view the consequences of each modified plan, and select among this larger set.
- the computer when monitoring the real injection reveals a deviation from the expected concentration changes, the computer may not only deduce corrections to the assumed field of transport parameters, and create revised predictions and warn if the results are unacceptable, but the computer may find a revised plan with more satisfactory results and (subject to user approval, or autonomously) implement the revisions while the injection is in progress.
- This variant of the invention requires the greatest speed, and is the most likely to require implementation with dedicated hardware optimized for the purpose of solving the necessary equations quickly.
- Drawing 7 shows the logic of the present invention.
- the relevant target tissue or body part is scanned (701) using one or more 3D imaging modalities such as magnetic resonance imaging, CT, ultrasound, etc.
- a physician arrives at a diagnosis and decides on a treatment plan (702).
- a choice of target limits (desired or undesired drug levels in different areas) is made (750) based on the scan.
- Scout injections (703) may be used to track the transport of neutral agents, from which transport behavior of actual therapeutic agents may be deduced by appropriate scaling.
- the physician makes a (virtual) selection (710) of device position within the body followed by selection (711) of a set of holes and membrane sizes and locations on the virtual device from which therapeutic agents are to be released.
- a choice of injection schedule is then made (712). Once these parameters are chosen, the transport of the drug out of the device and through the tissue surrounding it is computed (713).
- the resulting drug distribution is acceptable in the sense of matching the target limits chosen in 750. If it is not, the steps from selection of device position (710) to assessment of the predicted drug distribution (714) are repeated. If the predicted result is acceptable, the physical device is configured to the selected design (711) and placed (715) in the position selected (710). The time stepping of the therapeutic infusion schedule (712) is selected and the current time is updated (720). The current state of the infusion process within the subject is scanned (721) and a check is made (730) of whether the state matches the prediction (713) made earlier.
Abstract
A class of customizable injection devices or delivery instrumentswhose basic form is a stiff tube with holes of user-selectable size at several user-selectable places is described. The use of this device includes a method of selection and construction of a particular device from such a class of devices for a particular treatment procedure using computer-assisted means. Thus, the user may make selections among available or creatable choices (such as selection of hole size, hole location, number of holes, etc.), and a method can be practiced for making such user-selection serve the goals of delivery of materials such as drugs, cells, or of devices sufficiently small and numerous to be delivered in fluid suspension. The tube should be relatively stiff in the sense that it deflects by no more than an amount between 0° and 15° under the stresses of insertion and placement at the end of a catheter.
Description
DRUG DELIVERY AND CATHETER SYSTEMS. APPARATUS AND PROCESSES
BACKGROUND OF THE INVENTION Field of the Invention
It has long been common practice for practitioners using a medical device to customize it on site. For example, practitioners may take a straight-ended catheter from stock and reshape it with the fingers, to achieve greater efficacy in a particular task.
The present invention relates to a class of devices supplemented by computer supported designed-in variability, so that the user can make choices more accurately aimed at successfully accomplishing particular results.
The present invention relates to the field of delivery of materials into a patient, particularly at local sites within a patient using externally delivered devices to carry the materials to the desired site. The invention also relates to systems and processes for material delivery (especially pharmacologically active, view enhancing active or treatment active materials) to patients under Magnetic Resonance Imaging procedures.
2. Background of the Art
It is increasingly common and even necessary to administer a drug or other desired material to a carefully targeted part of the body. Currently such material is most often a solution or suspension of molecules, but in the future may include a suspension of nanoscopic devices. This targeted delivery is in contrast to conventional delivery methods where a drug is inserted into the bloodstream and treatment relies upon some of the drug finding the appropriate target. Targeted delivery has multiple advantages, when it can be done effectively. Much less of the drug is needed, which represents a double gain. Many drugs are costly, so the delivery of drugs in amounts greater than are needed for treating a specific area of a patient is wasteful and expensive. It is rare
that any drug is wholly without negative effects (e.g., side effects, with reference to the desired result of the primary drug). In some instances, these adverse side effects arise only where the drug reaches a specific tissue. Therefore, restricting the drug to a target that does not include tissue that can be damaged avoids side effects completely. Even where that degree of precision in delivery is not possible, the side effects may be far more acceptable if limited to a small region around the target, with reduced impact on the body at large, while delivering the desired result on the target tissue at full strength. Even where the side effects are not directly life-threatening, it can be important to avoid them. For example, it is desirable to keep cancer chemotherapy drugs from the sites where they cause nausea and hair loss. That practice would be good both for patient morale and for patient persistence in taking the drug.
Some drug therapies use very strong or even toxic materials in the treatment, and even cryogenic treatments can cause collateral damage as the cryogenic material contacts non-targeted tissue. Hormonal treatments, where picogram delivery volumes are used because of the strength or activity of the material delivered and/or the limited area of treatment desired, can cause significant collateral damage when inappropriately delivered. This is particularly true in intraparenchymal procedures and other intracranial procedures where collateral damage, even on a small physical scale, can be very serious. The majority of directed drug delivery systems tend to be essentially universal systems (intravenous or oral), ^discriminate local application (transdermal), or mdiscrirninate quasi-local (infusion from a catheter). Even the most advanced designs for MRI observable drug delivery as disclosed in U.S. Patent Nos. 6,026,316; and 5,964,705 can only properly position the catheter, but do not provide specific structures that can adjust the rate and position of drug delivery from the catheter other than by standard fluid pressure control. Many different functions and controls are desirable in drug delivery systems, particularly with respect to the rate and direction of drug delivery. It would be a poor operational protocol to require essentially random direction positioning on a catheter of delivery outlets for a drug, cell culture, nanoscopic
devices or other material, or require increased volumetric delivery, solely because the catheter could not be positioned with the outlets in an optimized position for desired delivery.
There are many different forms of drug delivery rate controls used in the medical field, both with intravenous, transdermal, and other forms of delivery. For example, U.S. Patent No. 6,029,083 describes a "fail-safe" iontophoretic drug delivery apparatus and a corresponding method is provided. The apparatus includes a current generating circuit for sending a current through a patch, error detection circuitry, and a control circuit. The control circuit controls the current generating circuit. When errors are detected in the apparatus, the control circuit stops the current and disables itself.
U.S. Patent No. 6,017,318 describes a feedback controlled drug delivery system that includes the automated sampling and analysis of a patient sample and dosing the patient based on the analysis. Automated sampling may be performed by direct analysis of the patient sample, such as for the measurement of a blood sample coagulation state or a glucose level. The drug delivery system includes a sample set that has a bidirectional patient tube that allows for delivery of the patient sample to an analyzer, and at another time, the infusion of a therapeutic drug. A controller receives a measurement from the analyzer, and based on that measurement, adjusts the delivery of the therapeutic fluid. The sample set has a quick-clear Leur fitting that allows for more effectively clearing a first fluid from a Leur fitting when starting a second fluid. The system also has a reagent cassette holder that protects, using a foam gasket, a reagent on a sample slide. Further, the system provides an interlock apparatus that assures a sample tube is occluded by either or both a slide clamp and by a platen arm compressing the sample tube to a peristaltic pump. U.S. Patent No. 6,007,518 describes a fluid delivery apparatus comprising:
(a) a fluid delivery assembly having an outlet for delivering fluid from the apparatus, said fluid delivery assembly including: (i) a base; (ii) means defining a conformable ullage overlaying said base for forming in
conjunction therewith a reservoir having an outlet in communication with said outlet of said fluid delivery assembly;
(iii) a cover assembly connected to said base, one of said cover assembly and said base having a receiving chamber interconnected with said reservoir; and (iv) a stored energy means for exerting forces on said means defining a conformable ullage, said stored energy means comprising at least one distensible membrane superimposed over said means defining a conformable ullage, said membrane being distensible by forces imparted thereon by said means defining a conformable ullage in response to fluids introduced into said reservoir, said forces establishing internal stresses within said distensible membrane, said stresses tending to return said distensible membrane toward a less distended configuration, said distensible membrane being generally conformable to the shape of said means defining a conformable ullage as said membrane is being distended thereby and also being generally conformable to the shape of said means defining a conformable ullage as said distensible membrane tends to return to said less distended configuration; and
(b) a fill assembly interconnected with said fluid delivery assembly for filling said reservoir.
U.S. Patent No. 5,997,527 describes a delivery device having a first chamber containing an osmotic agent, a membrane forming a wall of the first chamber through which fluid is imbibed by osmosis, a second chamber containing a beneficial agent to be delivered, and a moveable piston separating the two chambers. In fluid communication with the second chamber is an orifice which comprises a slit valve. In the presence of pressure, the beneficial agent pushes through the slit, opening up a channel for delivery of the beneficial agent and creating flow. Because the slit remains closed in the absence of flow (or when the pressure is below the pressure required to open the slit), back diffusion of external fluids is eliminated when the slit is closed, which prevents contamination of the beneficial agent in the second chamber by external fluids. In addition, forward diffusion of the beneficial agent out of the capsule is prevented when the slit is closed. The slit valve opens only to the minimum dimension
required to allow the flow generated by the osmotic pumping rate. The slit valve also allows a flow path to open around any obstruction in the slit valve to prevent clogging.
U.S. Patent No. 5,988,211 describes a method and apparatus for control of flow through an I.V. system, not a catheterized delivery system. That I.V. system comprises an I.V. Flow Controller incorporating an adjustable, differential pressure regulator that provides a constant but adjustable differential pressure across a fixed orifice. One end of the adjustment range provides shut-off and the other end full-flow. The adjustment range covers flow rates from zero to 250 ml/hr. At a given setting, the flow rate is independent of the total hydrostatic head height between the supply reservoir and a patient, provided the head height is greater than the pressure drop across the orifice at the maximum regulated flow rate, plus venous pressure, plus the pressure drop in the indwelling catheter.
U.S. Patent No. 5,983,130 describes an electrically controlled delivery system comprising an electrotransport agent delivery device for delivering a therapeutic agent through a body surface, and a method for increasing agent delivery efficiency, is provided. The device includes a current controller which delivers a pulsating electrotransport current and peak current density Imax, Imax being greater than a critical current density level Ic above which the body exhibits a non-transitory higher agent delivery efficiency. Methods for increasing electrotransport delivery efficiency (E) of an agent through a body surface by creation of a higher agent delivery efficiency state are also provided.
U.S. Patent No. 5,964,223 describes a method and apparatus for delivering a medicine to a patient via the patient's respiratory system with control and efficiency. A nebulization catheter is positioned in the patient's respiratory system so that a distal end of the nebulization catheter is in the respiratory system and a proximal end is outside the body. In a first aspect, the nebulization catheter may be used in conjunction with an endotracheal tube and preferably is removable from the endotracheal tube. The nebulization catheter conveys medicine in liquid form to the distal end at which location the medicine is nebulized by a pressurized gas or other nebulizing mechanism. The
nebulized medicine is conveyed to the patient's lungs by the patient's respiration which may be assisted by a ventilator. By producing the aerosol of the liquid medicine at a location inside the patient's respiratory system, the nebulizing catheter provides for increased efficiency and control of the dosage of medicine being delivered. In further aspects of the nebulizing catheter apparatus and method, alternative tip constructions, flow pulsation patterns, centering devices, sensing devices, and aspiration features afford greater efficiency and control of aerosolized medicine dosage delivery.
U.S. Patent No. 5,961,483 describes novel methods and devices for iontophoreticalfy administering therapeutic doses of cell adhesion receptor antagonists in a controlled manner through the skin. Such antagonist compounds include but are not limited to antagonists of the Ilb/IIIa and αvβ3 integrins and related cell surface adhesive protein receptors. The present invention includes iontophoretic delivery devices comprising cell adhesion receptor antagonists. Such methods and devices are useful, alone or in combination with other therapeutic agents, for the treatment of thromboembolic disorders, angiogenic disorders, inflammation, bone degradation, cancer metastasis, diabetic retinopathy, restenosis, macular degeneration, and other conditions mediated by cell adhesion and/or cell migration and/or angiogenesis.
U.S. Patent No. 5,941,868 describes Angiogenesis in cardiac and other tissues being promoted by the transmural delivery of angiogenic factors such as VEGF, FGF, EGF, and PDGF, through blood vessels and other body lumens into the surrounding tissue. Usually, the angiogenic factor is delivered using a catheter having infusion parts at its distal end. Optionally, the distal end of the catheter is radially expanded to engage the infusion parts directly against the blood vessel wall. A variety of catheter systems useful for the direct transmural infusion of angiogenic factors into the blood vessel wall are also well-described in the patent literature. Most commonly, balloon catheters having expandable distal ends capable of engaging the inner wall of a blood vessel and infusing an angiogenic factor directly therein are well-described in the patent literature. See, for example, U.S. Pat. Nos. 5,318,531; 5,304,121; 5,295,962; 5,286,254; 5,254,089; 5,213,576; 5,197,946; 5,087,244; 5,049,132; 5,021,044; 4,994,033; and
4,824,436. Catheters having spaced-apart or helical balloons for expansion within the lumen of a blood vessel and delivery of a therapeutic agent to the resulting isolated treatment site are described in U.S. Pat. Nos. 5,279,546; 5,226,888; 5,181,911; 4,824,436; and 4,636,195. A particular drug delivery catheter is commercially available under the trade name Dispatch™, from SciMed Life Systems, Inc., Maple Grove, Minn. Non-balloon drug deliver catheters are described in U.S. Pat. Nos. 5,180,366; 5,112,305; and 5,021,044; and PCT Publication WO 92/11890. UltrasonicaUy assisted drug delivery catheters (phonophoresis devices) are described in U.S. Pat. Nos. 5,362,309; 5,318,014; and 5,315,998. Other iontophoresis and phonophoresis drug delivery catheters are described in U.S. Pat. Nos. 5,304,120; 5,282,785; and 5,267,985. Finally, sleeve catheters having drug delivery lumens intended for use in combination with conventional angioplasty balloon catheters are described in U.S. Pat. Nos. 5,364,356 and 5,336,178.
U.S. Patent No. 5,906,502 describes an apparatus for accurately infusing fluids into a patient at specific rates over an extended period of time and the method for making same. The apparatus includes one or more dispensers of a low profile, laminate or layered construction each having a stored energy source in the form of a distensible membrane or an elastomeric cellular mass, which in cooperation with the base, defined a fluid chamber having a fluid inlet and a fluid outlet. The apparatus further includes, in lieu of a rigid ullage, a high novel, conformable ullage made of yieldable materials. The conformable ullage uniquely conforms to the shape of elastomeric membrane as the membrane returns to its less distended configuration. This arrangement will satisfy even the most stringent delivery tolerance requirements and will elegantly overcome the limitations of materials selection encountered in devices embodying the rigid ullage construction. Additionally, with the novel ullage construction, the ullage can be located either between the base and the fluid to be delivered, or alternatively, can be located between the elastomeric membrane and the fluid to be delivered. Further, a plurality of sub-reservoirs can be associated with a single ullage thereby making it possible to incorporate a wide variety of delivery profiles within a single device.
U.S. Patent Nos. 5,571,089; 5,542,926; and 5,522,800 describe a Low Profile Perfusion Catheter, for use in coronary angioplasty applications. Preferably, the catheter is provided with an inflatable dilatation balloon, and a perfusion lumen extending therethrough. The diameter of the perfusion lumen is enlargeable from a first, reduced diameter to a second, enlarged diameter. In one embodiment, an axially movable tubular support is movable within the lumen from a proximal, insertion position to a distal perfusion position. In another embodiment, the support is radially expandable. In a further embodiment, a porous drug delivery balloon is provided.
U.S. Patent No. 5,385,547 describes a drug delivery device for coupling a first container including a beneficial agent to a second member. In an embodiment, the device includes a substantially hollow member having a cannula mounted within a wall that divides the substantially hollow member into a first and second section. The first section includes means for receiving at least a portion of a first container. The substantially hollow member includes a wall that defines an exterior of the first section that is substantially flexible. A number of different cannula and flow path structures within the hollow member are possible.
U.S. Patent No. 5,498,236 describes a catheter suitable for introduction into a tubular tissue for dissolving blockages in such tissue. The catheter is particularly useful for removing thrombi within blood vessels. In accordance with the preferred embodiments, a combination of vibrating motion and injection of a lysing agent is utilized to break up blockages in vessels. The vessels may be veins, arteries, ducts, intestines, or any lumen within the body that may become blocked from the material that flows through it. As a particular example, dissolution of vascular thrombi is facilitated by advancing a catheter through the occluded vessel, the catheter causing a vibrating stirring action in and around the thrombus usually in combination with the dispensing of a thrombolytic agent such as urokinase into the thrombus. The catheter has an inflatable or expandable member near the distal tip which, when inflated or expanded, prevents the passage of dislodged thrombus around the catheter. The dislodged portions of thrombus are directed through a perfusion channel in the catheter,
where they are removed by filtration means housed within the perfusion channel before the blood exits the tip of the catheter. Catheters that allow both low frequency (1-1000 Hz) vibratory motion and delivery of such agents to a blockage and a method for using such catheters are disclosed. U.S. Patent Nos. 5,800,392 and 5,569,198 describe an apparatus for delivering an agent to a treatment area. The apparatus includes a catheter that has a distal portion and a proximal portion. The catheter defines a lumen. A pressure regulator is in fluid communication with the lumen. A selectively inflatable member is also in fluid communication with the lumen, and is formed from a membrane. The membrane has first and second portions. The first portion defines pores sized from about 0.05μ to about lμ and has a pore density from about 106 pores/cm2 to about 109 pores/cm2. The flux rate is from about 0.001 ml/(min-cm2-atm) to about 0.4 ml/(min-cm2-atm). The second portion is substantially impermeable.
U.S. Patent No. 5,783,793 describes a laser drilling process capable of producing a plurality of holes in a pharmaceutical dosage form at high speed. The process utilizes a high power CO2 laser steered by an acousto-optic deflector together with various mirrors and optical components to achieve the correct beam path geometry, in order to produce an unlimited number of holes through the surface or coating of a dosage form, at rates up to 100,000 units or more per hour. Even though restricted area targeting is highly desirable from a medical standpoint, this type of procedure adds to the traditional complexity of computing dosage and delivery rates. Instead of a single figure of blood concentration, controlled by the rates at which the drug enters and at which it diffuses, flows and is absorbed, metabolized or excreted by various tissues, concentration becomes a distinct time- varying number at each part of the body. Since the effects of a drug vary in complex ways on concentration (scopolamine, for example, is an anti-nausea drug in a narrow range of levels, neither too high nor too low), its administration must ensure that the concentration at the target tissue is correct for the desired effect. At the same time, the concentration at other points must minimize undesired effects (often, but not always, by
minimizing concentration at such points). Planning treatments and procedures thus requires prediction and flexibility of drug (or material) delivery.
Prediction at real-time speed of drug transport is becoming possible due to improvements in computing machinery and in methodology (see the commonly asigned copending patent application of R. Raghavan et al. , "A Method and Apparatus for Targeting Material Delivery to Tissue", SLWK docket no. 723.032US1 and also the journal article by Paul Morrison et al, "High-flow microinfusion: tissue penetration and pharmacodynamics", American Journal of Physiology 266, p. R292-R305, 1994). This type of procedure permits planning not only of the timing and quantity of active material to be administered, but enables customized design of the form of the administering device for the best possible effect. The present invention provides designs for improved delivery systems that assist in improving the ability of the practitioner to implement the planned procedure.
Given scan data (magnetic resonance, CAT, etc.) on the anatomy and physiology of a patient, and in some cases on the transport of labeled materials in 'scout' injections, one can construct a numerical model of transport which permits prediction of the evolving concentration level of the material to be administered.
Such prediction requires a model of the transport process in tissue, as described in the above identified copending patent application "A Method and Apparatus for Targeting Material Delivery to Tissue". It also requires boundary conditions that specify the pressure or flow rate of fluid at sufficient distance from the injection device, and at the place(s) where the fluid leaves the device and enters the tissue.
Brief Summary of the Invention The present invention defines a class of customizable injection devices or delivery instruments whose basic form is a stiff tube with holes of user-selectable size at several user-selectable places, whose use includes a method of selection and construction of a particular device from such a class of devices for a particular treatment procedure using computer-assisted means. Thus, the user may make selections among
the available choices (such as selection of hole size, selection of hole location, etc.), and a method can be practiced for making such user-selection serve the goals of delivery of materials such as drugs, cells, or of devices sufficiently small and numerous to be delivered in fluid suspension. The tube is relatively stiff in the sense that it deflects by an amount between 0° and 15° under the stresses of insertion and placement at the end of a catheter, and varies less than 5 or less than 10% per cent in cross-sectional area when so deflected to the maximum of about 15 degrees.
The selection method may be practiced as follows. The user selects target tissues where the presence of the material is desired, and selects maximum and minimum target concentrations, and identifies tissues vulnerable to the material to be introduced, with maximum permitted concentrations identified in the region of the vulnerable tissues. This target information may be retained in the user's consciousness, or input to the machine by use of an interface, such as a visual interface (e.g., with pre-procedure image information or real-time image information). The user may then specify a hole pattern (e.g., a number of holes, a distribution of holes, the size of holes, the position of holes, etc.), and see the predicted result with a selected time course of imposed pressure (or imposed flow rate) of the material at a specified concentration in injected fluid. Alternatively, e.g., if the desired concentration criteria have been communicated to a computer, the user may request the system to explore different patterns (as defined above) and injection plans to produce a result satisfying the input criteria, or coming as close to such satisfaction as is acceptable or possible.
Brief Description of the Drawings Drawing 1. A tube tip with holes in various positions and dimensions, and membranes of various thicknesses between them.
Drawing 2. A tube tip with holes in various positions and dimensions, arranged by revolving collars over holes created in manufacture.
Drawing 3. A tube tip with holes in various positions and dimensions, created by assembling cylindrical units with holes and membranes of different sizes.
Drawing 4. A ramrod device for placing permeable barriers in a tube at preplanned positions.
Drawing 5. Concentrations of a diffusing material around a multi-hole catheter.
Drawing 6. A field of coefficients (here represented by a single number at each point, with a 2D grid standing for three dimensions) governing the transport of injected material.
Drawing 7. The flow chart of the computation and interaction procedure of the invention.
DETAILED DESCRIPTION OF THE INVENTION
Delivery Instrument
The physical component or device of the present invention is a tube (Drawing 1), rigid or sufficiently stiff to retain its internal cross-section (with a reduction not to exceed 10% and preferably equal to or less than 7% or 5%) when bent through a deflection of up to 15°, and deflecting by at most this amount under the stresses usual for an inserted catheter. The limitation on the change in cross-section is of significance because flexing of the device will often occur during procedures. If the cross-section alters, that would introduce a variation in device performance that would complicate the implementation of controls, as the flow and delivery rate properties of the device would change without intent. This tube is pre-engineered with holes 101 of adjustable sizes and positions, or capable of being drilled with holes of chosen sizes and positions. The tube may be mounted on a rigid or flexible channel 102 through which fluid containing dissolved or suspended material capable of moving through or onto bodily tissue may be transmitted to the interior of said tube. That material then passes through said holes to contact the tissue. Within said tube may be placed one or more control mechanisms that can regulate the passage of material through the holes. Regulation includes all rates between complete blockage of material through the hole to allowing free passage of material through the hole. Such regulation and control mechanisms may be mechanical, electromechanical, or quasi-mechanical in nature. A purely mechanical control
mechanism would be a slidable or rotatable cap that would obscure some holes, all holes, or portions of holes. For example, with a top of the element having twenty holes for release of material, there could be a cap with fifty holes distributed thereon. Rotation of the cap through ninety, one hundred twenty, one hundred sixty, one hundred eighty, or up to three hundred and sixty degrees would expose various portions or numbers of the twenty holes. For example, at a position defined as zero degree rotation, zero holes might be exposed (that is all twenty holes would be covered, preventing material delivery). At a five degree rotation, 1-3 holes at a specific position relative to the device would be exposed to allow delivery of material from those exposed holes. At a ten degree rotation, 3-5 holes at specific positions relative to the exterior of the device would be exposed. At a fifteen degree rotation, 5-8 holes at specific positions would be exposed to release material. At a twenty degree rotation, 9-12 holes would be exposed. At a thirty degree rotation, 12-15 holes would be exposed at specific positions on the outside of the device. At a forty-five degree rotation, 15-18 holes would be exposed, and at a sixty degree rotation, 18-20 holes would be exposed. With further degrees of rotation (or with intermediate degrees of rotation), different numbers of holes would be exposed (or more covered), and the position or relative location of those holes could be changed. For example, the first forty five degrees of rotation could expose holes in one cross-section quadrant of the device, the next forty-five degrees expose holes in another cross-section quadrant of the device, and so forth, with all four quadrants being individually or collectively exposed. In this manner, if the visualization of the delivery of the drug or material from the device (as taught in U.S. Patent No. 6,026,316) shows that the alignment of the device (e.g., a catheter) is delivering material too broadly (radially at all points along the tube surface) or in a quadrant facing away from the target tissue), the device may be remotely controlled by this mechanical control to redirect the output of material more closely towards the target tissue. Mechanical control could be effected by manipulation or mechanical control of a guidewire attached to the cap. Electromechanical control could employ electronically remote controlled servos or robotics that move caps, covers or the like around holes in the surface of the
device. Micromotors could shift one or more hole-covering or hole-blocking elements to increase or decrease the rate of flow of material and the direction of flow of material from the device. A quasimechanical system would include resistively heated sections where flow would increase because of thermal expansion around or by holes; remotely initiated elastic deformation of caps to adjust the size of holes, and the like. Membranes may also be used that are electrically or thermally or elastically responsive to adjust flow rates through them. For example, in Figure 1, membranes 103 or blocks 104 of permeable material separate the holes, modifying the transmission characteristics of the fluid between them. The fabrication of the instrument may use any of a number of methods familiar to those skilled in the art. A wide selection of options may be pre-manufactured, saving on-site time at the expense of increased stock and storage costs. The preferred embodiment of the present invention is local customization, whereby the holes may be made or adjusted by the use of local equipment acting on a small set of standard parts, by various methods. Those described here are selected precisely for their suitability to on-the-spot fabrication of the instrument, rather than requiring factory production facilities. For instance, as noted earlier, the adjustability of the holes may be achieved in several ways. In one implementation, a plain tube is inserted in a jig and holes drilled into it with conical drill bits, so that the depth controls the hole diameter. Evidently this function can be performed by a small automated system, but equally a plan of the holes could be printed out on adhesive paper. The user would attach this printed hole distribution map to the tube, and drill the holes by hand, extending the current practice of radiologists in adjusting the active end of a catheter. Alternatively, the distribution of holes could be imaged on a photolithographic resist layer and the image developed and etched to produce the appropriate hole distribution.
Alternatively, and mentioned here for purposes of illustration only, the tube may be manufactured with a closely spaced sequence of cylindrical collars (Drawing 2, in an exploded view). Under each collar 201 the tube is ringed with holes 202, alternating with regions 203 of un-pierced tube. Each collar has a single hole 204, which may be
aligned partially or completely with any one of the holes, enabling the user to create a hole of varying cross-section in any one of a set of positions around the tube. To avoid unplanned leakage this requires precise engineering of a throwaway item, and is thus well suited to profitable medical engineering. The tube may also be assembled (Drawing 3) by sticking together short cylindrical segments 301 from a stock 310 of such pieces, with holes 311 and without holes 312, of varying lengths. In this implementation, some of the pieces 312 may contain permeable membranes 316 or blocks 317 whose permeability is marked on the outside, so that these may be added by the same assembly process. An optional cap 320 would allow the user to block the hole 321 at the end. If joining of the segments is performed by a heat- welding system in which one part must pass down the lumen of the combined tube, which would be blocked by the inclusion of permeable membranes, such membranes may be added later, as described in the discussion of Drawing 4. Holes may be photohthographically etched, laser etched, chemically milled, electrical discharge milled (EDM), or mechanically milled by other available procedures.
Where the tube is supplied as an unbroken cylinder rather than as pieces, Drawing 4 shows how permeable or discontinuously permeable slidable elements (permeable cylindrical blocks 201 or membranes 202) capable of lodging in the interior may be pushed down the tube to the required depth, using a calibrated ramrod 410 whose tip 411 pushes an element inside the tube. Again, by redesigning the distribution of holes and selecting appropriate hole patterns in the slidable elements, the direction and rate of the material release can be controlled with significant specificity.
In each design approach, it is often appropriate to include elements (e.g., MR markers or MR responsive markers) that make the orientation of the tube visible to the imaging system in use, as twisting the tube turns side holes to face different parts of the tissue. In certain cases, the resulting change in concentration distribution can be significant.
Pressures in the Tube
Given the pressures or the flow rates at the holes, and their cross-sections, the methods described in commonly assigned copending application bearing attorney's docket number 723.032US1 in the name of R. Raghavan et al, and titled "A Method and Apparatus for Targeting Material Dehvery to Tissue", filed on May 8, 2000, having
U.S. Serial No. 09/566,478, which disclosure is incorporated herein in its entirety, serve to compute the resulting transport of material through tissue.
These pressures and flow rates are the result of interaction among the tube, the surrounding tissue and the fluid already present, but to a certain approximation they may be computed for the tube on the assumption of a fixed background pressure in the surrounding tissue. Specifically, let us number the holes according to their distance from the inlet end. If more than one port(s) has the same distance from the inlet end, then the more than one port(s) is or are mathematically replaced by a single port with a cross-section area equal to the total cross-section area of all such ports. (For the interior of the tube, the results are equivalent.) Now, let
A= Area of cross section of the catheter
V= Velocity of fluid infusion
Pa= Ambient pressure K= Hydraulic permeability of the catheter
L= Length of the catheter t= Thickness of the catheter wall
77= Coefficient of viscosity of the fluid
L(= Distance between port i and (i-Y) ,= Cross sectional area of port i
Ki= Tissue hydraulic permeability at port i qt= Velocity of fluid outflow at port i vt= Velocity of fluid flow at port i along the catheter p,= Pressure at port i
N= Total number of ports (including the outlet port)
We ignore possible variability of the hydraulic permeability along the length of the catheter and use the value (i?2/8) that is appropriate for steady Poiseuille flow in a tube with circular cross section of radius in case we are modeling viscous laminar flow. In the porous medium, Darcy's law relates fluid velocity to the pressure gradient and we may use this to express the outflow velocity at a port in terms of the pressure gradient across the port. So the fluid velocity vt at port i along the catheter is
v = - Vp = _ K (pl+1 -Pl) η η +ι
(i)
whereas the velocity of fluid outflow q, at port i is
(2)
The fluid is assumed incompressible. Therefore the total fluid volume flow must equal the total fluid volume inflow minus the fluid flow through all the previous ports. At any arbitrary port i except the outlet end, we may write
(3) or
K -(P,-pl+i) = Vη+ ^ KJ J(pa-Pj)
J(+l tA
(4) and at the outlet end, we have the flux conservation equation
N rc.a, ∑^L(pa-pJ)=Vη tA
(5)
This set of (N+1) equations can be represented in matrix form as
Solving equation (6) gives the pressure at all the ports, and at the inlet and outlet ends. Since only pressure differences influence the flow, we have to fix (specify) one of the pressures; it is convenient to fix the ambient pressure (possibly to zero, in which case all other pressures are measured with respect to the ambient pressure). These pressure values obtained from (6) can be plugged back in the Darcy equations to give fluid outflow velocities at the ports, and thereby the fluid volume flow.
Planning system Given a customization system for specifying and fabricating tubes with a chosen spacing of holes and inter-hole membranes (with specified cross-sections and permeabilities), as above, and a means of computing the transport of injected material within tissue for conditions specified at the exit points in the injection instrument, such as that in the aforementioned "A Method and Apparatus for Targeting Material Delivery to Tissue", the user may select a particular instrument optimal for a given treatment. The user-selection element of the present invention may proceed as follows:
Image guidance permits a user injecting a material such as a drug solution or a suspension of cells or nanodevices, or any material that can flow and diffuse in the brain, to place a delivery instrument such as a catheter into (for example) a human brain, and see where it is located relative to scan-visible structures. In present practice, the user makes a plan for injection, deteπriining the quantity of the material to be loaded into the delivery system, the pressure or flow rate (perhaps variable) at which the substance is to be injected, and the time over which the flow is to be maintained. The objective of such a plan is to deliver the substance in desired quantities in 'target' tissues, often while minimizing the amount delivered to non-target tissues (where it
would be wasted) and to vulnerable tissues where the substance would do harm. It is also desirable to avoid excessive fluid pressure and to minimize the extent and duration of the resulting edema (swelling) of the tissue encountered by the material and the fluid carrying it. Commonly, this plan is entered into a computer which will control the injection process, but direct hand control is also possible. This plan is then followed, with a change only if visually inspected images (e.g., U.S. Patent No. 6,026,316) of the diffusing material makes clear that concentration, pressure or edema is not following the course expected by the user. Since the evolving concentration, pressure and edema are 3D scalar fields in the midst of complex 3D structures, visual inspection requires a strong grasp of the 3D relationships revealed by scan data. Current 3D display techniques do not display these relationships clearly enough to guarantee fast comprehension and appropriately swift action by the medical user. It is rare that undesired consequences are seen fast enough to limit their scope. The present invention replaces or augments such visual inspection by enabling the computer to enter this part of the control loop, with optimal planning of the tube outlets as well as of the injection schedule.
At a simple level of control in the present invention, the user specifies a position for placement of the device (as is now done), and also specifies magnitude, distribution and location of holes and membranes. The user then specifies an injection schedule (quantity, duration, pressure/flow-rate) to the computer. We refer to these combined specified features (a specification) as a plan. The computer then solves the transport problem on the assumption that this plan is followed, using the field of parameters established as in the above identified copending U.S. Patent Application "A Method and Apparatus for Targeting Material Delivery to Tissue", or otherwise, together with available subsidiary data such as background interstitial fluid pressure and blood pressure to specify boundary conditions. The system displays the predicted values of concentration, pressure and edema, and the user has the opportunity to examine them at non-crisis speed and determine whether they are satisfactory. If not, the user repeatedly
changes the plan, until an acceptable result is predicted. At this point, the schedule is implemented under computer control.
At a more strongly supported level of control, the user modifies the hole and membrane distribution by the use of a graphical user interface and specifies target tissues by marking them (for example, by using a 2D or 3D mouse to click on points, specifying ball-shaped regions of adjustable radius; or, outlining a target region; or, moving a 2D or 3D mouse through an image of the region of interest and seeing a resulting spray-can-like superposed image showing the intensity of target values so input for corresponding points, etc. Minimum and maximum target concentrations may be input separately. Similaryly, the user may mark vulnerable tissues, and quantify their vulnerability to excess concentration, pressure or edema. The user inputs a plan as above, and the computer predicts the resulting concentrations. In this mode, the computer display includes markers for agreement with the user's goals, so that visual inspection is guided to possible regions of concern. When a chosen plan is implemented, using scan-visibility of the injected substance the computer can monitor deviation from the expected time course of concentration, and detecting problems earlier (and thus more usefully) than visual monitoring. Where deviation beyond a threshold level is detected, the computer derives revised estimates for the transport parameters in the tissue and deduces revised predictions for the results of the plan. If these involve values pre-specified by the user as unacceptable, the computer may pause the injection for new user input.
At a higher level again, where the computer is capable of carrying out multiple predictive simulations of transport in available time, it may search the space of possible plans for the plan(s) with the result most quantitatively desirable according to the user- specified result. (For example, it may begin by heuristically choosing an initial plan, perhaps a standard one, and investigate the predicted result of successive changes in it, changing the current reference plan where it sees improved results. In general the physics will not allow exact achievement of a particular user-specified target concentration, pressure or edema, so this is not well posed as an inverse problem. The
system's goal must be to find a plan whose results are within user-specified limits.) Such plan(s) may be presented to the user, to be accepted or rejected by key-strokes, mouse click, voice, or other input means devoid of quantitative detail; or, the user may quantitatively modify the plan(s), view the consequences of each modified plan, and select among this larger set.
Where the computer is thus capable of generating plans adjusted to user goals, when monitoring the real injection reveals a deviation from the expected concentration changes, the computer may not only deduce corrections to the assumed field of transport parameters, and create revised predictions and warn if the results are unacceptable, but the computer may find a revised plan with more satisfactory results and (subject to user approval, or autonomously) implement the revisions while the injection is in progress.
This variant of the invention requires the greatest speed, and is the most likely to require implementation with dedicated hardware optimized for the purpose of solving the necessary equations quickly.
Flow of the method
In summary, Drawing 7 shows the logic of the present invention. First, the relevant target tissue or body part is scanned (701) using one or more 3D imaging modalities such as magnetic resonance imaging, CT, ultrasound, etc. From an analysis of the scan, a physician arrives at a diagnosis and decides on a treatment plan (702). A choice of target limits (desired or undesired drug levels in different areas) is made (750) based on the scan. Scout injections (703) may be used to track the transport of neutral agents, from which transport behavior of actual therapeutic agents may be deduced by appropriate scaling. Next, the physician makes a (virtual) selection (710) of device position within the body followed by selection (711) of a set of holes and membrane sizes and locations on the virtual device from which therapeutic agents are to be released. A choice of injection schedule is then made (712). Once these parameters are
chosen, the transport of the drug out of the device and through the tissue surrounding it is computed (713).
Following the computation, it is assessed (714) whether the resulting drug distribution is acceptable in the sense of matching the target limits chosen in 750. If it is not, the steps from selection of device position (710) to assessment of the predicted drug distribution (714) are repeated. If the predicted result is acceptable, the physical device is configured to the selected design (711) and placed (715) in the position selected (710). The time stepping of the therapeutic infusion schedule (712) is selected and the current time is updated (720). The current state of the infusion process within the subject is scanned (721) and a check is made (730) of whether the state matches the prediction (713) made earlier. If it does, then it is further checked (737) whether the injection schedule (712) has been completed; if it is not, the steps from time step update (720) to checking the match with the prediction (730) are repeated. If the injection schedule (712) has been completed, the injection process is concluded (740). If the current scanned state (721) does not match the prediction (713), a new prediction is generated (731) and a check is made (732) of whether the new prediction (731) is acceptable. If it is, the steps from time step update (720) to check of acceptability (732) are repeated. If the new prediction (731) is not acceptable, it is determined (734) whether a revised infusion schedule may yield more acceptable results. If a suitable revised schedule is found, this is chosen as the new infusion schedule (733) and the process reverts to time step selection and update (720). If no such revised schedule is found, an emergency stop (738) is arrived at and the infusion process is concluded (740).
Claims
1. A tube for delivering materials to internal tissue of a patient, said tube comprising a lumen for carrying the material, holes from said lumen to an exterior surface of the tube, and control elements for modifying flow rates of the material from said lumen through said holes.
2. The tube of claim 1 wherein at least one control element comprises a membrane that can be moved relative to a hole to modify a flow rate through that hole.
3. The tube of claim 1 wherein said control element comprises a movable element that can block or expose a hole.
4. The tube of claim 1 wherein said control element comprises a movable element within the lumen.
5. The tube of claim 1 wherein said control element comprises a movable element on an exterior surface of said tube.
6. The tube of claim 3 wherein said control element comprises a movable element on an exterior surface of said tube.
7. The tube of claim 1 wherein said control element positions membranes with predetermined material conductivity adjacent to at least one hole to control material flow through that hole.
8. The tube of Claim 1 where said tube is assembled from a set of cylindrical sub- units, at least two of said cylindrical subunits having different arrangements of side holes.
9. The tube of Claim 1 where said tube is assembled from a set of cylindrical sub- units, at least two of said cylindrical subunits having different and control elements.
10. A method for delivering material to tissue within a patient comprising inserting the device of claim 1 into a patient, and controlling a rate of flow of the material through a hole in the tube by controlling the control element.
11. A method for specifying a modifiable class of tubes for the dehvery of materials capable of passing through bodily tissue in solution or suspension in a biocompatible fluid, with outlet holes variable in number, size and placement, optional membranes being inserted between said outlet holes to modify the flow.
12. The tube of Claim 1, where the body of the tube is a flexible catheter, capable of following a blood vessel, ventricle or other curved lumen in the body.
13. The tube of Claim 1 , where the body of the tube is a rigid probe, capable of being forced through soft tissue in a straight or curved line.
14. The tube of Claim 1 where delivery parameters having been predetermined, a determination is then made to design specific distributions and locations of opening on the tube to effect those delivery parameters, and the holes are created according to design effecting those delivery parameters.
15. The tube of Claim 1 where the holes are created according to predetermined design parameters, and delivery control is provided by fully or partially openable sliding covers for holes, with a capability that less than all holes in the tube may be selected for delivery.
16. The method of claim 10 where a medical practitioner selects the number, size and placement of the holes, and the penetrability and placement of internal membranes, selection based on computer predictions as to the distribution of delivered material when material in a chosen concentration is passed down the tube with a selected time course of pressure or of pumping rate.
17. The method of claim 10 wherein a planned position of the tube within the body is shown on a computer display of a computer system, and a medical practitioner uses a graphical interface to specify regions where high concentration of the delivered material is respectively desired or to be avoided, or where it is essential to limit pressure above background, edema or the time for which either occurs, and the computer system uses a model of the diffusion and transport process to define a set of holes and membranes that will result in satisfying these criteria, and then the designed set of holes and/or membranes are provided in a tube.
18. The process of claim 17 where the graphical interface uses a mouse, tablet or similar 2D input device to control an image on a screen in which slices of a body scan are displayed.
19. The process of claim 17 where the graphical interface uses a 3d input device to control an image in a stereographic display in which volume-rendered images of a body scan are displayed.
20. The process of claim 10 wherein a medical practitioner specifies only the region in which a rigid tube is to be placed, together with regions where piercing by the tube would be unacceptable, and a computer defines an entry path which achieves ancillary criteria including at least one parameter selected from the group consisting of a) minimal damage en route to the target region, and b) minimal time spent drilling through bone to open a pathway.
21. The method of claim 17 wherein imaging is used at the time of insertion of a catheter to confirm that the catheter has been placed in the planned position.
22. The method of claim 10 wherein a real-time visualization of distributed material is used to confirm that distribution of material is occurring in accordance with a predetermined plan, and where deviation from said predetermined plan is found, a controller modifies the pumping rate or pressure if appropriate.
23. The method of claim 21 wherein said controller is a computer.
24. The tube of Claim 2 where said tube is assembled from a set of cylindrical sub- units, at least two of said cylindrical subunits having different arrangements of side holes.
25. The tube of Claim 2 where said tube is assembled from a set of cylindrical sub- units, at least two of said cylindrical subunits having different and control elements.
25. The tube of claim 3 said tube is assembled from at least two cylindrical subunits, each of said at least two cylindrical subunits having different flow properties through surfaces of the cylinders.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2001277120A AU2001277120A1 (en) | 2000-07-26 | 2001-07-24 | Drug delivery and catheter systems, apparatus and processes |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US09/626,059 | 2000-07-26 | ||
US09/626,059 US6464662B1 (en) | 2000-07-26 | 2000-07-26 | Drug delivery and catheter systems, apparatus and processes |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2002007809A1 true WO2002007809A1 (en) | 2002-01-31 |
WO2002007809B1 WO2002007809B1 (en) | 2002-04-11 |
Family
ID=24508780
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2001/023187 WO2002007809A1 (en) | 2000-07-26 | 2001-07-24 | Drug delivery and catheter systems, apparatus and processes |
Country Status (3)
Country | Link |
---|---|
US (1) | US6464662B1 (en) |
AU (1) | AU2001277120A1 (en) |
WO (1) | WO2002007809A1 (en) |
Cited By (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7252654B2 (en) | 1999-12-20 | 2007-08-07 | Tricardia, Llc | Apparatus with weeping tip and method of use |
WO2013056006A3 (en) * | 2011-10-14 | 2013-07-04 | Intuitive Surgical Operations, Inc. | Catheter systems |
US9387048B2 (en) | 2011-10-14 | 2016-07-12 | Intuitive Surgical Operations, Inc. | Catheter sensor systems |
US9452276B2 (en) | 2011-10-14 | 2016-09-27 | Intuitive Surgical Operations, Inc. | Catheter with removable vision probe |
US10238837B2 (en) | 2011-10-14 | 2019-03-26 | Intuitive Surgical Operations, Inc. | Catheters with control modes for interchangeable probes |
CN110114107A (en) * | 2017-01-31 | 2019-08-09 | 日本来富恩株式会社 | Foley's tube |
WO2019222441A1 (en) | 2018-05-16 | 2019-11-21 | Voyager Therapeutics, Inc. | Aav serotypes for brain specific payload delivery |
EP3632923A1 (en) | 2015-01-16 | 2020-04-08 | Voyager Therapeutics, Inc. | Central nervous system targeting polynucleotides |
US10682070B2 (en) | 2011-10-14 | 2020-06-16 | Intuitive Surgical Operations, Inc. | Electromagnetic sensor with probe and guide sensing elements |
Families Citing this family (32)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0300922D0 (en) * | 2003-01-15 | 2003-02-12 | Mirada Solutions Ltd | System for controlling medical data acquistion processes |
US7494477B2 (en) * | 2003-09-02 | 2009-02-24 | Pulsecath B.V. | Catheter pump, catheter and fittings therefore and methods of using a catheter pump |
EP1673127B1 (en) * | 2003-09-02 | 2014-07-02 | PulseCath B.V. | Catheter pump |
US7848543B2 (en) * | 2004-02-05 | 2010-12-07 | Brainlab Ag | Method and system for prediction and management of material and information transport in an organism |
WO2006015091A2 (en) * | 2004-07-28 | 2006-02-09 | University Of Virginia Patent Foundation | Coaxial catheter systems for transference of medium |
US9901413B2 (en) * | 2004-10-15 | 2018-02-27 | Brainlab Ag | Targeted infusion of agents for treatment of ALS |
US9907485B2 (en) * | 2004-10-15 | 2018-03-06 | Brainlab Ag | Targeted immunization and plaque destruction against Alzheimer's disease |
US9924888B2 (en) * | 2004-10-15 | 2018-03-27 | Brainlab Ag | Targeted infusion of agents against parkinson's disease |
US9694170B2 (en) | 2005-09-19 | 2017-07-04 | Brainlab Ag | Method and device for planning a direct infusion into hepatic tissue |
US7713232B2 (en) * | 2005-11-04 | 2010-05-11 | Medrad, Inc. | System for washing and processing of cells for delivery thereof to tissue |
US8182444B2 (en) * | 2005-11-04 | 2012-05-22 | Medrad, Inc. | Delivery of agents such as cells to tissue |
US8112292B2 (en) | 2006-04-21 | 2012-02-07 | Medtronic Navigation, Inc. | Method and apparatus for optimizing a therapy |
WO2008029407A2 (en) * | 2006-09-06 | 2008-03-13 | Yeda Research And Development Co. Ltd. | Apparatus and method for monitoring drug delivery |
US8660635B2 (en) | 2006-09-29 | 2014-02-25 | Medtronic, Inc. | Method and apparatus for optimizing a computer assisted surgical procedure |
US20080086111A1 (en) * | 2006-10-09 | 2008-04-10 | Medrad, Inc. | Fluid delivery systems and volume metering in cell delivery |
US20080161824A1 (en) * | 2006-12-27 | 2008-07-03 | Howmedica Osteonics Corp. | System and method for performing femoral sizing through navigation |
US8790317B2 (en) * | 2007-02-13 | 2014-07-29 | Cornell University | Convection enhanced delivery apparatus, method, and application |
DE602008003941D1 (en) | 2007-04-13 | 2011-01-27 | Brainlab Ag | Method and device for planning local administration of a drug |
WO2008144232A2 (en) | 2007-05-18 | 2008-11-27 | The Johns Hopkins University | A treatment simulator for brain diseases and method of use thereof |
EP2163218A1 (en) * | 2008-09-16 | 2010-03-17 | Osyris Medical | Device for treating part of a human or animal body comprising an instrument for dispensing and/or an instrument for locally sucking up treatment doses and means for controlling dosimetry |
US8165658B2 (en) * | 2008-09-26 | 2012-04-24 | Medtronic, Inc. | Method and apparatus for positioning a guide relative to a base |
AU2012290129B2 (en) | 2011-08-01 | 2016-10-13 | Alcyone Therapeutics, Inc. | Microfluidic drug delivery devices |
US9020224B2 (en) | 2012-04-27 | 2015-04-28 | Medtronic, Inc. | Volume of efficacy model capture |
US9393364B2 (en) | 2012-07-17 | 2016-07-19 | Cook Medical Technologies Llc | Multi-lumen biologic-delivering device |
US9393361B2 (en) | 2012-12-14 | 2016-07-19 | Medtronic, Inc. | Method to determine a material distribution |
US9008752B2 (en) | 2012-12-14 | 2015-04-14 | Medtronic, Inc. | Method to determine distribution of a material by an infused magnetic resonance image contrast agent |
ES2869328T3 (en) | 2012-12-18 | 2021-10-25 | Alcyone Lifesciences Inc | Devices and methods for reducing or preventing reflux in an administration system |
JP6483655B2 (en) | 2013-03-15 | 2019-03-13 | マフィン・インコーポレイテッドMuffin Incorporated | Cell injection needle |
WO2014204954A1 (en) | 2013-06-17 | 2014-12-24 | Alcyone Lifesciences, Inc. | Methods and devices for protecting catheter tips and stereotactic fixtures for microcatheters |
US10441770B2 (en) | 2013-07-31 | 2019-10-15 | Alcyone Lifesciences, Inc. | Systems and methods for drug delivery, treatment, and monitoring |
US10806396B2 (en) | 2015-01-26 | 2020-10-20 | Alcyone Lifesciences, Inc. | Drug delivery methods with tracer |
JP2019502473A (en) | 2016-01-04 | 2019-01-31 | アルキオーネ・ライフサイエンシズ・インコーポレイテッドAlcyone Lifesciences, Inc. | Method and apparatus for treating stroke |
Citations (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0406901A1 (en) * | 1989-07-07 | 1991-01-09 | Advanced Cardiovascular Systems, Inc. | Intravascular catheter having an adjustable length infusion section to deliver therapeutic fluid |
US5380307A (en) * | 1992-09-30 | 1995-01-10 | Target Therapeutics, Inc. | Catheter with atraumatic drug delivery tip |
EP0810003A2 (en) * | 1996-05-30 | 1997-12-03 | Target Therapeutics, Inc. | Kink-resistant braided catheter with distal side holes |
WO1998022175A1 (en) * | 1996-11-21 | 1998-05-28 | Sachdeva Rohit C L | Modular balloon catheter |
US5964705A (en) | 1997-08-22 | 1999-10-12 | Image-Guided Drug Delivery System, Inc. | MR-compatible medical devices |
US5983130A (en) | 1995-06-07 | 1999-11-09 | Alza Corporation | Electrotransport agent delivery method and apparatus |
US5988211A (en) | 1998-07-06 | 1999-11-23 | Randolph W. Cornell | I.V. flow controller |
US5997527A (en) | 1997-03-24 | 1999-12-07 | Alza Corporation | Self adjustable exit port |
US6007518A (en) | 1995-12-22 | 1999-12-28 | Science Incorporated | Fluid delivery device with conformable ullage and fill assembly |
US6017318A (en) | 1995-02-07 | 2000-01-25 | Gensia Automedics, Inc. | Feedback controlled drug delivery system |
US6026316A (en) | 1997-05-15 | 2000-02-15 | Regents Of The University Of Minnesota | Method and apparatus for use with MR imaging |
US6029083A (en) | 1997-04-04 | 2000-02-22 | Becton, Dickinson And Company | Circuit and method for automatically turning off an iontophoresis system |
Family Cites Families (35)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3592184A (en) * | 1969-12-16 | 1971-07-13 | David H Watkins | Heart assist method and catheter |
US3888249A (en) * | 1973-11-02 | 1975-06-10 | David L Spencer | Arterial infusion catheter |
US4636195A (en) | 1982-04-02 | 1987-01-13 | Harvey Wolinsky | Method and apparatus for removing arterial constriction |
US4824436A (en) | 1985-04-09 | 1989-04-25 | Harvey Wolinsky | Method for the prevention of restenosis |
US5021044A (en) | 1989-01-30 | 1991-06-04 | Advanced Cardiovascular Systems, Inc. | Catheter for even distribution of therapeutic fluids |
US5087244A (en) | 1989-01-31 | 1992-02-11 | C. R. Bard, Inc. | Catheter and method for locally applying medication to the wall of a blood vessel or other body lumen |
US4994033A (en) | 1989-05-25 | 1991-02-19 | Schneider (Usa) Inc. | Intravascular drug delivery dilatation catheter |
HU212760B (en) | 1989-06-20 | 1997-02-28 | Denes | Method and device for the apportion of chemical materials into the vein wall |
US5304121A (en) | 1990-12-28 | 1994-04-19 | Boston Scientific Corporation | Drug delivery system making use of a hydrogel polymer coating |
US5049132A (en) | 1990-01-08 | 1991-09-17 | Cordis Corporation | Balloon catheter for delivering therapeutic agents |
ATE123658T1 (en) | 1990-06-15 | 1995-06-15 | Cortrak Medical Inc | DEVICE FOR DISPENSING MEDICATIONS. |
US5279546A (en) | 1990-06-27 | 1994-01-18 | Lake Region Manufacturing Company, Inc. | Thrombolysis catheter system |
US5197946A (en) | 1990-06-27 | 1993-03-30 | Shunro Tachibana | Injection instrument with ultrasonic oscillating element |
US5180366A (en) | 1990-10-10 | 1993-01-19 | Woods W T | Apparatus and method for angioplasty and for preventing re-stenosis |
US5102402A (en) | 1991-01-04 | 1992-04-07 | Medtronic, Inc. | Releasable coatings on balloon catheters |
US5181911A (en) | 1991-04-22 | 1993-01-26 | Shturman Technologies, Inc. | Helical balloon perfusion angioplasty catheter |
US5213576A (en) | 1991-06-11 | 1993-05-25 | Cordis Corporation | Therapeutic porous balloon catheter |
US5318531A (en) | 1991-06-11 | 1994-06-07 | Cordis Corporation | Infusion balloon catheter |
AU656628B2 (en) | 1991-10-18 | 1995-02-09 | United States Surgical Corporation | Endoscopic surgical instrument for aspiration and irrigation |
US5226888A (en) | 1991-10-25 | 1993-07-13 | Michelle Arney | Coiled, perfusion balloon catheter |
US5254089A (en) | 1992-04-02 | 1993-10-19 | Boston Scientific Corp. | Medication dispensing balloon catheter |
US5368566A (en) | 1992-04-29 | 1994-11-29 | Cardiovascular Dynamics, Inc. | Delivery and temporary stent catheter having a reinforced perfusion lumen |
US5380273A (en) | 1992-05-19 | 1995-01-10 | Dubrul; Will R. | Vibrating catheter |
US5354291A (en) | 1992-10-09 | 1994-10-11 | Symbiosis Corporation | Probe for endoscopic suction-irrigation instruments having a proximal port for receiving an additional probe therethrough |
US5336178A (en) | 1992-11-02 | 1994-08-09 | Localmed, Inc. | Intravascular catheter with infusion array |
US5385547A (en) | 1992-11-19 | 1995-01-31 | Baxter International Inc. | Adaptor for drug delivery |
US5344402A (en) | 1993-06-30 | 1994-09-06 | Cardiovascular Dynamics, Inc. | Low profile perfusion catheter |
DE4324218A1 (en) | 1993-07-19 | 1995-01-26 | Bavaria Med Tech | Cuff catheter |
US5415636A (en) * | 1994-04-13 | 1995-05-16 | Schneider (Usa) Inc | Dilation-drug delivery catheter |
ZA954936B (en) | 1994-06-17 | 1996-02-27 | Trudell Medical Ltd | Nebulizing catheter system and methods of use and manufacture |
US5569198A (en) | 1995-01-23 | 1996-10-29 | Cortrak Medical Inc. | Microporous catheter |
EP0871512A1 (en) | 1995-12-22 | 1998-10-21 | Localmed, Inc. | Localized intravascular delivery of growth factors for promotion of angiogenesis |
US5783793A (en) | 1996-02-29 | 1998-07-21 | Merck & Co., Inc. | Process for producing a plurality of holes in dosage forms using a laser beam deflected by an acousto-optic deflector |
WO1997048444A1 (en) | 1996-06-19 | 1997-12-24 | Becton Dickinson And Company | Iontophoretic delivery of cell adhesion inhibitors |
US5906502A (en) | 1997-12-08 | 1999-05-25 | Porta Systems Corp. | Two wire termination connection strip |
-
2000
- 2000-07-26 US US09/626,059 patent/US6464662B1/en not_active Expired - Lifetime
-
2001
- 2001-07-24 AU AU2001277120A patent/AU2001277120A1/en not_active Abandoned
- 2001-07-24 WO PCT/US2001/023187 patent/WO2002007809A1/en active Application Filing
Patent Citations (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0406901A1 (en) * | 1989-07-07 | 1991-01-09 | Advanced Cardiovascular Systems, Inc. | Intravascular catheter having an adjustable length infusion section to deliver therapeutic fluid |
US5380307A (en) * | 1992-09-30 | 1995-01-10 | Target Therapeutics, Inc. | Catheter with atraumatic drug delivery tip |
US6017318A (en) | 1995-02-07 | 2000-01-25 | Gensia Automedics, Inc. | Feedback controlled drug delivery system |
US5983130A (en) | 1995-06-07 | 1999-11-09 | Alza Corporation | Electrotransport agent delivery method and apparatus |
US6007518A (en) | 1995-12-22 | 1999-12-28 | Science Incorporated | Fluid delivery device with conformable ullage and fill assembly |
EP0810003A2 (en) * | 1996-05-30 | 1997-12-03 | Target Therapeutics, Inc. | Kink-resistant braided catheter with distal side holes |
WO1998022175A1 (en) * | 1996-11-21 | 1998-05-28 | Sachdeva Rohit C L | Modular balloon catheter |
US5997527A (en) | 1997-03-24 | 1999-12-07 | Alza Corporation | Self adjustable exit port |
US6029083A (en) | 1997-04-04 | 2000-02-22 | Becton, Dickinson And Company | Circuit and method for automatically turning off an iontophoresis system |
US6026316A (en) | 1997-05-15 | 2000-02-15 | Regents Of The University Of Minnesota | Method and apparatus for use with MR imaging |
US5964705A (en) | 1997-08-22 | 1999-10-12 | Image-Guided Drug Delivery System, Inc. | MR-compatible medical devices |
US5988211A (en) | 1998-07-06 | 1999-11-23 | Randolph W. Cornell | I.V. flow controller |
Cited By (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7252654B2 (en) | 1999-12-20 | 2007-08-07 | Tricardia, Llc | Apparatus with weeping tip and method of use |
US10653866B2 (en) | 2011-10-14 | 2020-05-19 | Intuitive Surgical Operations, Inc. | Catheter with removable vision probe |
US10744303B2 (en) | 2011-10-14 | 2020-08-18 | Intuitive Surgical Operations, Inc. | Catheters with control modes for interchangeable probes |
US9452276B2 (en) | 2011-10-14 | 2016-09-27 | Intuitive Surgical Operations, Inc. | Catheter with removable vision probe |
US10238837B2 (en) | 2011-10-14 | 2019-03-26 | Intuitive Surgical Operations, Inc. | Catheters with control modes for interchangeable probes |
US11918340B2 (en) | 2011-10-14 | 2024-03-05 | Intuitive Surgical Opeartions, Inc. | Electromagnetic sensor with probe and guide sensing elements |
US11684758B2 (en) | 2011-10-14 | 2023-06-27 | Intuitive Surgical Operations, Inc. | Catheter with removable vision probe |
US10568700B2 (en) | 2011-10-14 | 2020-02-25 | Intuitive Surgical Operations, Inc. | Catheter sensor systems |
US9387048B2 (en) | 2011-10-14 | 2016-07-12 | Intuitive Surgical Operations, Inc. | Catheter sensor systems |
WO2013056006A3 (en) * | 2011-10-14 | 2013-07-04 | Intuitive Surgical Operations, Inc. | Catheter systems |
US10682070B2 (en) | 2011-10-14 | 2020-06-16 | Intuitive Surgical Operations, Inc. | Electromagnetic sensor with probe and guide sensing elements |
EP3632923A1 (en) | 2015-01-16 | 2020-04-08 | Voyager Therapeutics, Inc. | Central nervous system targeting polynucleotides |
CN110114107B (en) * | 2017-01-31 | 2021-08-17 | 日本来富恩株式会社 | Balloon catheter |
CN110114107A (en) * | 2017-01-31 | 2019-08-09 | 日本来富恩株式会社 | Foley's tube |
WO2019222441A1 (en) | 2018-05-16 | 2019-11-21 | Voyager Therapeutics, Inc. | Aav serotypes for brain specific payload delivery |
Also Published As
Publication number | Publication date |
---|---|
US6464662B1 (en) | 2002-10-15 |
AU2001277120A1 (en) | 2002-02-05 |
WO2002007809B1 (en) | 2002-04-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6572579B1 (en) | Drug delivery and catheter systems, apparatus and processes | |
US6464662B1 (en) | Drug delivery and catheter systems, apparatus and processes | |
US20230173224A1 (en) | Drug Delivery Systems and Methods | |
US20200275948A1 (en) | Drug delivery systems and methods | |
AU2018235381B2 (en) | Fluid exchange system and related methods | |
US6969373B2 (en) | Syringe system | |
JP5670439B2 (en) | System and method for delivering therapeutic agents | |
US8979801B2 (en) | Microcatheter devices and methods for targeted substance delivery | |
US8715240B2 (en) | Apparatus and method for convection enhanced therapeutic delivery | |
US20140288414A1 (en) | Devices, systems and methods for acute or chronic delivery of substances or apparatus to extravascular treatment sites | |
US20020072706A1 (en) | Transluminal drug delivery catheter | |
US20090281486A1 (en) | Apparatus and methods for delivering therapeutic agents | |
EP2133108B1 (en) | Pulsatile flux drug delivery | |
JPH02500888A (en) | Improvements in retrograde perfusion | |
CA2241615A1 (en) | Catheters | |
US20230211137A1 (en) | Wearable micropump for therapeutic drug delivery | |
AU2002311816A1 (en) | Syringe system |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AU CA JP |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
AK | Designated states |
Kind code of ref document: B1 Designated state(s): AU CA JP |
|
AL | Designated countries for regional patents |
Kind code of ref document: B1 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR |
|
B | Later publication of amended claims | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
122 | Ep: pct application non-entry in european phase | ||
NENP | Non-entry into the national phase |
Ref country code: JP |